KRAS and pancreatic neoplasm: The process of docking K-Ras gene-associated RALGDS inhibitor pancreatic cancer-targeted drugs involves predicting the binding affinity, finding of allosteric site of the protein by the aid of an eraser algorithm and the type of interaction of these newly identified lead skeletons by computationally evaluating their interactions with the RALGDS protein29.